Novartis ( NYSE:NVS ), the Swiss pharmaceutical giant, has made a strategic move in the field of cancer treatment by securing a licensing agreement with Arvinas, a U.S. biotech company. The deal, valued at up to $1.01 billion, grants Novartis access to Arvinas' experimental prostate cancer drug, ARV-766. This collaboration marks Novartis' ( NYSE:NVS ) continued...
Looking to capitalise on momentum created from a bounce from that short term trend line. Limit order at 86.85 above last week's prices. Ultimate target would be the 100 zone for 1:3.5 risk to reward ratio.
Immediate targets 94, 95. Invalidation 79. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels...
Looks like we have a an end to a zigzag here. Technically, we have not left FibChannel, hence the approach is risky. If the picture is right, we may see one or more impulses upwards. Wait and see. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with...
Welcome to our Weekly V2-Trade Setup ( NVS ) ! - 4 HOUR Bearish market breakdown.. DAILY Expecting another wave to the upside. WEEKLY Looking for a midterm push. - STOCK SETUP BUY NVS ENTRY LEVEL @ 83.15 SL @ 82.15 TP @ Open Max Risk: 0.5% - 1%! (Remember to add a few pips to all levels - different Brokers!) Leave us a comment or like to keep our content...
$MMM, $AMP, $GOOGL, $GE, $AMD, $COF, $HAS, $V, $TWTR, $UPS, $RTX, $NVS $MMM - 3M - reported EPS of $2,45/share - beat estimates of $2.21/share - revenue of $8.94B +7.09% YoY Organic local-currency sales up 6.3% YoY Operating CF of $1.9B Adjusted FCF of $1.5B (20%) YoY Returned $1.4B to shareholders in dividends Industrial FCF tops estimates Narrows FY21 EPS...
The Directional Movement Index is showing Bullish sentiment on the DMI indicator and the EMA @ 55 fib. If the Bears crossover the EMA then close long position. Gives you excellent entry point with minimal stop loss.
NVS is a long term reliable dividend paying hold, but I try to be careful with pharmas. A lot of possible catalysts that can change the direction too soon. This is purely a trend line analysis. I see good indicators from trend lines in play and looks like the stock will re test the $98 high again before either a move up or down. I expect it to break downward by...
Greetings Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, feel free to send us message (inbox). Pra Trading : - Please care for Money Management - Have a good psychology - Do not be hurry to open position and do not do...
Novartis (NVS) reported earnings last week. A Golden Cross event (considered Bullish) occurred in the stock. The chart includes a technical and fundamental analysis of Novartis.
NVS was among the high cap losers yesterday on the renewed coronavirus tensions and pulled back dramatically (-6.90%). This however can be the buy opportunity of the next several months as it hit the 1D MA200 (orange line) and is approaching the Higher Low trend line of the 1W Channel Up (RSI = 45.378, MACD = 1.640, ADX = 65.865). Even though the MACD indicated...
$MDCO has been having a banner year with the stock up over 200%. We think this rally still has legs and that $MDCO is going to keep climbing after Monday's huge breakout. Here's a look at what drove Monday's breakout. Results from a Phase 3 clinical trial, ORION-9, evaluating the effect of The Medicines Company's (MDCO +2.3%) inclisiran on reducing "bad"...
RGNX sold off 12% today on news of a partial clinical hold on an NVS gene therapy trial using its vector. After reading the press release I think this was an overreaction and the stock price will bounce back swiftly into RGNX earnings catalyst on 11/08/2019. It is sold off right to the bottom of its channel making for a beautiful setup!
Pharmaceutical stocks represents a defensive asset when a positive market cycle is about to finish or when it is foreseen a cycle less positive than the previous one. In such context pharma stocks should have an advantage because of inelastic demand for such goods. Novartis ($NVS,$NOVN) is one of the candidate to break up as the price is moving in a triangle...
Really watching this one early in the morning. Looks beautiful.